Hopital Prive Drome-Ardeche
- Address
- 15 Rue Jacques Delpeuch, 26000 Valence, France
Male Urogenital Diseases
At Hopital Prive Drome-Ardeche, the oncology team explores therapeutic strategies for castration‑resistant prostate cancer, seeking to improve overall survival through innovative drug combinations.
- Aspirin and statin regimen evaluated for survival benefit
- Novel oral therapy trial for premature ejaculation
These efforts highlight a dedication to advancing care for male urogenital conditions.
Neoplasms
The department pursues advanced immunotherapy approaches in solid tumors, including agents that block the PD-1 pathway to enhance patient outcomes.
- Advanced non‑small cell lung cancer – immunotherapy with radiation
- Triple negative breast cancer – adjuvant pembrolizumab combination
- Recurrent/metastatic squamous cell carcinoma of the head and neck – new checkpoint inhibitor comparisons
Collaboration with European research networks supports rapid translation of findings into clinical practice.
Reproductive and Urinary Physiological Phenomena
Research on functional health focuses on the reproductive and urinary physiological processes, aiming to deliver treatments that improve daily quality of life.
- Placebo‑controlled trial of BP1.4979 for premature ejaculation
- Exploratory study of urinary biomarkers linked to treatment response
Patient‑centered designs ensure relevance to real‑world health concerns.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Prive Drome-Ardeche
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 3 | Unknown | 2024-02-26 | 2025-01-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.